Searchable abstracts of presentations at key conferences in endocrinology

ea0050s2.3 | When receptors go rogue | SFEBES2017

Extra-nuclear estrogen receptors in breast cancer

Levin Ellis

Steroid receptors (SR) respond to binding of their ligands with rapid signal transduction resulting from engaging extra-nuclear receptors. This occurs in addition to the conventional aspects of steroids/nuclear SR that regulate gene transcription. In breast cancer, estrogen and progesterone receptors (ER, PR) are present at the plasma membrane in addition to the nucleus. Here the receptors activate many pathways as G-protein coupled receptors, resulting in epigenetic and genet...

ea0050s2.3 | When receptors go rogue | SFEBES2017

Extra-nuclear estrogen receptors in breast cancer

Levin Ellis

Steroid receptors (SR) respond to binding of their ligands with rapid signal transduction resulting from engaging extra-nuclear receptors. This occurs in addition to the conventional aspects of steroids/nuclear SR that regulate gene transcription. In breast cancer, estrogen and progesterone receptors (ER, PR) are present at the plasma membrane in addition to the nucleus. Here the receptors activate many pathways as G-protein coupled receptors, resulting in epigenetic and genet...

ea0094p49 | Endocrine Cancer and Late Effects | SFEBES2023

Neuroendocrine cancer: An ideal patient pathway

Jervis Nikie , Bouvier-Ellis Catherine

Neuroendocrine cancers represent the tenth most prevalent type of cancer in England. However, people with neuroendocrine cancer currently face significant inequities throughout the entire care pathway – from suspected cancer to follow-up care. Despite expert clinical guidelines, there is no currently available national Neuroendocrine Cancer Patient Referral and Care Pathway. Guiding principles of optimal patient pathways include the promotion of earlier, accurate diagnosi...

ea0081p565 | Calcium and Bone | ECE2022

A case of severe hypercalcaemia secondary to primary hyperparathyroidism responding to steroids

Mathew Susan , Ellis Tracey , Jude Edward

Case History: A 57 year old male, who was known to have primary hyperparathyroidism was admitted to hospital due to hypercalcaemia on routine blood tests (adjusted S. calcium- 3.44 mmol/l.) He had no symptoms due to hypercalcaemia. This was his 5th admission since the diagnosis 18 months ago, each admission requiring treatment with IV fluids and IV bisphosphonates. SESTAMIBI and ultrasound scans of the thyroid and parathyroids had previously localised a likely right inferior p...

ea0028p65 | Clinical practice/governance and case reports | SFEBES2012

A streamlined strategy for the biochemical investigation of adrenal incidentalomas

Ellis Nicola , Wright Dianne , Peacey Steven

It is important to identify whether benign adrenal incidentalomas are hormonally active. Traditionally, investigations were arranged during the first medical consultation and relied heavily on the patient remembering a considerable number of instructions. The patient was required to collect urine bottles from pathology, a prescription from pharmacy and perform multiple tests including renin, which was often incorrectly performed in outpatients. Due to the cumbersome nature of ...

ea0011s34 | Clinical lessons from novel aspects of G protein-coupled receptors signalling | ECE2006

How the pattern of GPCR co-expression can regulate function

Milligan G , Pediani J , Ellis J

The pharmacology and function of G protein-coupled receptors (GPCRs) is frequently studied following expression of a single receptor in heterologous cell lines. However, many GPCRs are co-expressed. We wished to investigate how expression of pairs of receptors might modulate their function. Using a Human Embryonic Kidney 293 cell line in which the CB1 cannabinoid receptor was expressed constitutively and in which varying levels of expression of the orexin-1 receptor could be i...

ea0011p713 | Reproduction | ECE2006

Hyperprolactinaemia due to big prolactin

Ahlquist JA , Ellis AR , Fahie-Wilson MN

Prolactin is present in serum in a variety of forms defined by different molecular masses. Macroprolactin is the best-known variant, a high molecular mass (150–170 kD) form of prolactin usually representing a prolactin–IgG complex which reacts in immunoassays causing apparent hyperprolactinaemia. Big-prolactin is a smaller high molecular mass (50–60 kDa) form of prolactin found more commonly than macroprolactin; however, the origin and significance of big-prolac...

ea0007p168 | Neuroendocrinology and behaviour | BES2004

Variability in GH assays undermines the value of consensus criteria for the diagnosis of adult GH deficiency and acromegaly

Pokrajac-Simeunovic A , Wieringa G , Ellis A , Trainer P

There is increasing reliance on published consensus criteria for clinical decision-making in states of GH excess and deficiency. NICE eligibility criteria for GH treatment include a peak GH response <9 mU/L during an ITT. To determine the adequacy of GH assay performance for diagnosing GH deficiency (GHD), we have assessed the variability in 101 UKNEQAS reported results from a single sample with a value close to 9.0 mU/L. For all laboratories (n=101) median GH was 11.1 mU/L...

ea0096p12 | Section | UKINETS2023

Co-production of Patient Information: a model for future practice?

Nikie Jervis Miss , Bouvier-Ellis Mrs Catherine

Background: Liver transplantation for cancer is evolving offering new opportunities for selected Neuroendocrine Cancer patients in terms of improvements in survival and quality of life. According to the British Medical Association, good quality patient information is fundamental to effective, patient-centred, quality care. It rightly considers patients as partners in their care, empowering them to have a better understanding of their health or illness, to make...

ea0031p362 | Thyroid | SFEBES2013

Does closer monitoring of thyroid function post radioiodine reduce the severity of hypothyroidism when first detected?

Thida Myat , Ellis N R , Wright D , Peacey S R

We have previously shown that the current guidelines for monitoring thyroid function post radioiodine (RI), may not detect hypothyroidism until it has become severe, in a significant proportion of cases (J Endocrinol Invest 2012 35 82–86). An alternative more intense follow-up strategy was used whereby patients had TSH and FT4 measured at 4-week intervals post RI for 6 months. Endocrine specialist nurse-led telephone and nurse-led out-...